Affiliation:
1. National Cancer Institute, Nagpur, Maharashtra, India
Abstract
Microsatellite instability (MSI) and mismatch repair (MMR) deficiency are important biomarkers in colorectal cancer (CRC) that have clinical implications for patient management and treatment. MMR deficiency can lead to MSI, which is characterized by alterations in the length of microsatellite DNA sequences. Clinical applications of MMR deficiency in colorectal adenocarcinoma are as a prognostic marker as well as Predictive marker for adjuvant chemotherapy and immunotherapy. To assess the MMR status of colorectal adenocarcinomas.: This was a retrospective study of 127 colorectal adenocarcinomas cases. All the samples were either biopsies or surgically resected tumor tissues from patients of Carcinoma Colon and rectum. Immunohistochemistry was performed on Roche Ventana Benchmark XT autostainer.: MLH-1, PMS2, MSH2 and MSH6 expression was retained in the tumor cells in 106 cases and it was lost in 21 cases. Among various clinicopathological variables, tumor site and AJCC pStage were found to be significantly associated with dMMR tumors. Patients of colorectal adenocarcinomas were benefited by MMR testing as it influenced the adjuvant treatment in all Stage IIA cases as well as all metastatic cases. Incorporating MMR testing into routine clinical practice can help optimize patient management and treatment strategies in CRC.
Publisher
IP Innovative Publication Pvt Ltd
Reference14 articles.
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Estimates of worldwide burden of cancer in 2008: GLOBOCAN.Int J Cancer 2008;127(12):2893-917
2. Sinicrope FA, Sargent DJ, Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications.Clin Cancer Res 2012;18(6):1506-12
3. Yuan L, Chi Y, Chen W, Chen X, Wei P, Sheng W, Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency.Int J Clin Exp Med 2015;8(11):20988-1000
4. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw 2021;19(3):329-59
5. Svrcek M, Lascols O, Cohen R, Collura A, Jonchère V, Fléjou JF, MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.Bull Cancer 2019;106(2):119-28